Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 6, 2015, Pages

  Sasongko, Teguh H ^a   Nagalla, Srikanth ^b   Ballas, Samir K ^b  

^a SCHOOL OF HEALTH SCIENCES   (Malaysia)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; POTASSIUM; PROTEIN;

COUGHING; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; KIDNEY INJURY; MEAN ARTERIAL PRESSURE; META ANALYSIS; MICROALBUMINURIA; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; REVIEW; SHOULDER PAIN; SICKLE CELL ANEMIA; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; ALBUMINURIA; BLOOD; COMPLICATION; FEMALE; MALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL INSUFFICIENCY; URINE;

ALBUMINURIA; ANEMIA, SICKLE CELL; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; CREATININE; FEMALE; HUMANS; MALE; POTASSIUM; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY;

EID: 84957793098     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009191.pub3     Document Type: Review

References (60)

1. Foucan L, Bourhis V, Bangou J, Merault L, Etienne-Julan M, Salmi RL. A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia. American Journal of Medicine 1998;104(4):339-42.
2. Aoki RY, Saad ST. Enalapril reduces the albuminuria in patients with sickle cell disease. American Journal of Medicine 1995;98(5):432-5.
3. Falk RJ, Scheinman J, Phillips G, Orringer E, Johnson A, Jennette JC. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. New England Journal of Medicine 1992;326(14):910-5.
4. Fitzhugh CD, Wigfall DR, Ware RE. Enalapril and hydroxyurea therapy for children with sickle nephropathy. Pediatric Blood and Cancer 2005;45(7):982-5.
5. McKie KT, Hanevold CD, Hernandez C, Waller JL, Ortiz L, McKie KM. Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease. Journal of Pediatric Hematology/Oncology 2007;29(3):140-4.
6. Al Hosani H, Salah M, Osman HM, Faraq HM, Anvery SM. Incidence of haemoglobinopathies detected through neonatal screening in the United Arab Emirates. La Revue de Santé de la Méditerranée Orientale 2005;11(3):300-7.
7. American Kidney Fund. High Blood Pressure (Hypertension). www.kidneyfund.org/kidney-health/are-you-at-risk/high-blood-pressure.html (accessed 24 October 2010).
8. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. Journal of Clinical Investigation 1986;77(6):1993-2000.
9. Ataga KI, Orringer EP. Renal Abnormalities in Sickle Cell Disease. American Journal of Hematology 2000;63(4):205-11.
10. Ataga KI, Brittain JE, Moore D, Jones SK, Hulkower B, Strayhorn D, et al. Urinary Albumin Excretion is Associated with PulmonaryHypertension in Sickle Cell Disease: Potential Role of SolubleFms-Like Tyrosine Kinase-1. European Journal of Haematology 2010;85(3):257-63.
11. Becton LJ, Kalpathi RV, Rackoff E, Disco D, Orak JK, Jackson SM, et al. Prevalence and clinical correlates of microalbuminuria in children with sickle cell disease. Pediatric Nephrology 2010;25(8):1505-11.
12. Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: national and state estimates. American Journal of Hematology 2009;85(1):77-8.
13. Chandar J, Abitbol C, Montane B, Zilleruelo G. Angiotensin blockade as a sole treatment for proteinuric kidney disease in children. Nephrology, Dialysis, Transplantation 2007 May;22(5):1332-7.
14. Diallo D, Tchernia G. Sickle Cell Disease in Africa. Current Opinion in Hematology 2002;9(2):111-6.
15. Donner A, Klar N. Issues in the meta-analysis of cluster randomised trials. Statistics in Medicine 2002;21(19):2971-80.
16. Driss A, Asare KO, Hibbert JM, Gee B, Adamkiewics TV, Stiles JK. Sickle cell disease in the post genomic era: a monogenic disease with a polygenic phenotype. Genomic Insights 2009;2009(2):23-48.
17. Elbourne DR, Altman DG, Higgins PT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
18. Etteldorf JN, Tuttle AW, Clayton GW. Renal function studies in pediatrics. 1. Renal hemodynamics in children with sickle cell anemia. American Medical Association. American Journal of Diseases of Children 1952;83(2):185-91.
19. Falk RJ, Jennette JC. Sickle cell nephropathy. Advances in Nephrology from the Necker Hospital 1994;23:133-47.
20. Fernandes AP, Januario JN, Canqussu CB, de Macedo DL, Viana MB. Mortality of children with sickle cell disease: a population study. Jornal de Pediatria 2010;86(4):279-84.
21. Forrest S, Kim A, Carbonella J, Pashankar F. Proteinuria is Associated With Elevated Tricuspid Regurgitant Jet Velocity inChildren With Sickle Cell Disease. Pediatr Blood Cancer 2012;58:937-940.
22. Guasch A, Cua M, Mitch ME. Early detection and the course of glomerular injury in patients with sickle cell anemia. Kidney International 1996;49(3):786-91.
23. Guasch A, Cua M, You W, Mitch WE. Sickle cell anaemia causes a distinct pattern of glomerular dysfunction. Kidney International 1997;51(3):826-33.
24. Guasch A, Zayas CF, Eckman JR, et al. Evidence that microdeletions in the alpha globin gene protect against the development of sickle cell glomerulopathy in humans. Journal of the American Society of Nephrology 1999;10(5):1014-9.
25. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
26. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration. [: Available from www.cochrane-handbook.org]
27. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet 2010;375(9722):1296-309.
28. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Reviews 2007;21(1):37-47.
29. Kolesnyk I, Struijk DG, Dekker FW, Krediet RT. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with chronic kidney disease. Netherlands Journal of Medicine 2010;68(1):15-23.
30. Kotiah SD, Ballas SK. Investigational drugs in sickle cell anemia. Expert Opinion of Investigational Drugs 2009;18(12):1-12.
31. Lerma EV. Sickle Cell Nephropathy: Treatment & Medication. http://emedicine.medscape.com/article/247004-treatment (accessed 17 October 2010).
32. Lottenberg R, Hassell KL. An evidence-based approach to the treatment of adults with sickle cell disease. Hematology American Society of Hematology Education Program 2005:58-65.
33. MedlinePlus End-stage kidney disease. www.nlm.nih.gov/medlineplus/ency/article/000500.htm (accessed 24 October 2010).
34. National Screening Committee. NHS Sickle Cell and Thalassemia Screening Programme. London: NHS Sickle Cell and Thalassaemia Screening Programme, 2006.
35. National Institute of Health, National Heart, Lung and Blood Institute, Division of Blood Diseases and Resources. The Management of Sickle Cell Disease. 4th Edition. NIH Publication, June 2002.
36. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97(2):439-45.
37. Pawloski JR, Hess DT, Stamler JS. Impaired vasodilation by red blood cells in sickle cell disease. Proceedings of the National Academy of Sciences of the United States of America 2005;102(7):2531-6.
38. Pham PT, Pham PC, Wilkinson AH, Lew SQ. Renal abnormalities in sickle cell disease. Kidney International 2000;57(1):1-8.
39. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. New England Journal of Medicine 1994;330(23):1639-44.
40. Powars DR, Elliott-Mills DD, Chan L, Niland J, Hiti AL, Opas LM, et al. Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. Annals of Internal Medicine 1991;115(8):614-20.
41. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood 2010;115(17):3447-52. [DOI: 10.1182/blood-2009-07-233700]
42. Reid JL, Rubin PC, Walters MR. Lecture Notes; Clinical Pharmacology and Therapeutics. 7th Edition. Massachusetts: Blackwell Publishing, 2006.
43. Rxmed ACE inhibitors General Monograph. www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20A)/ACE%20INHIBITORS.html (accessed 17 October 2010).
44. Saborio P, Scheinman JI. Sickle Cell Nephropathy. Journal of the American Society of Nephrology 1999;10(1):187-92.
45. Scheinman JI. Sickle Cell Disease and the kidney. Nature Clinical Practice Nephrology 2009;5(2):78-88.
46. Schnog JB, Duits AJ, Muskiet FAJ, Cate HE, Rojer RA, Brandjes DPM. Sickle cell disease; a general overview. Netherlands Journal of Medicine 2004;62(10):364-74.
47. Serjeant GR. Sickle Cell Disease. 2nd Edition. New York: Oxford Medical Publications, 1992.
48. American Academy of Family Physicians. Essentials of the Diagnosis of Heart Failure. www.aafp.org/afp/20000301/1319.html (accessed on 14 March 2011).
49. Sharpe CC, Thein SL. Sickle cell nephropathy - a practical approach. British Journal of Haematology 2011;155(3):287-97.
50. Steinberg MH. Management of sickle cell disease. New England Journal of Medicine 1999;340(13):1021-30.
51. Steinberg MH. Pathophysiologically based drug treatment of sickle cell disease. TRENDS in Pharmacological Sciences 2006;27(4):204-10.
52. Steiner C, Miller J. HCUP Statistical Brief #21. Sickle Cell Disease Patients in U.S. Hospitals, 2004. www.hcup-us.ahrq.gov/reports/statbriefs/sb21.pdf (accessed 15 April 2011).
53. Waller DG, Renwick AG, Hillier K. Medical Pharmacology and Therapeutics. 2nd Edition. London: Elsevier Saunders, 2005.
54. Ware RE, Rees RC, Sarnaik SA, Iyer RV, Alvarez OA, Casella JF, et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Journal of Pediatrics 2010;156(1):66-70.
55. Comprehensive Metabolic Panel. www.webmd.com/a-to-z-guides/comprehensive-metabolic-panel-topic-overview July 9 2009 (accessed on 14 March 2011).
56. Wesson DE. The initiation and progression of sickle cell nephropathy. Kidney International 2002;61(6):2277-86.
57. Wigfall DR, Ware RE, Burchinal MR, Kinney TR, Foreman JW. Prevalence and clinical correlates of glomerulopathy in children with sickle cell disease. Journal of Pediatrics 2000;136(6):749-53.
58. Xie D, Joffe MM, Brunelli SM, Beck J, Chertow GM, Fink JC, et al. A comparison of change in measured and estimated glomerular filtration rate in patients with nondiabetic kidney disease. Clinical Journal of the American Society of Nephrology 2008;3(5):1332-8.
59. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. Journal of Clinical Investigation 1986;77(6):1925-30.
60. Sasongko TH, Nagalla S, Ballas SK. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD009191.pub2]